Abstract Library

#4157 Decoding and targeting of metabolic heterogeneity in pancreatic neuroendocrine tumors (PanNETs): MCT1 and MCT4 in the crosshair for precision therapy

Introduction: Mechanisms driving progression from indolent to aggressive and metastatic disease in PanNET are largely unknown. Recent transcriptome and epigenome analyses suggest a stepwise progression model leading to enhanced proliferation, de-differentiation, and metabolic reprogramming. However, the metabolic landscape at different stages and the therapeutic potential of targeting metabolic proteins remain largely uncharacterized.

Conference:

Presenting Author: Sadowski M

Authors: Bräutigam K, Straub J, Bihi A, Andreasi V, Kirchner P,

Keywords: metabolic heterogeneity, 3D model, precision medicine, metabolic subtype, PanNET, hypoxia, lactate efflux, microvessel density, MCT1/MCT4,

#3725 Progression of pancreatic neuroendocrine tumors (PanNETs) to metastatic disease is associated with MCT4 expression and metabolic heterogeneity

Introduction: Up to 50% of patients with PanNETs present with metastasis at time of diagnosis or relapse after surgery, with highly variable dynamics. The mechanisms driving progression from indolent to metastatic disease are largely unknown. Although having great potential for providing novel therapeutic targets, the metabolic landscape at different tumor stages is only poorly understood. Transcriptome and epigenome analyses of PanNET indicate a potential stepwise progression, which is associated with enhanced proliferation, dedifferentiation and hallmarks of hypoxia.

Conference:

Presenting Author: Sadowski M

Authors: Sadowski M, Bräutigam K, Straub J, Andreasi V, Kirchner P,

Keywords: MCT4, metabolic subtypes, aggressive PanNET, patient-derived tumoroid,

#3692 Improvement of lung NET management through standardized care – A Swiss nationwide observational study

Introduction: Typical (TC) and atypical carcinoids (AC) are the most common neuroendocrine tumors (NETs) of the lung. Being a rare disease, the management of these tumors varies widely among Swiss centers. The impact of guidelines introduced in 2015 is unknown.

Conference:

Presenting Author: Schmidlin M

Authors: Schmidlin M, Sadowski S, Siebenhüner A, Wild D, Christ E,

Keywords: pulmonary carcinoid, survival analysis, registry,

#1857 Association between Neuroendocrine Tumors (NETs) Biomarkers and Tumor Burden Based on Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Measurements

Introduction: No study has yet assessed the utility of biochemical biomarkers for evaluating NET burden using 68Ga-DOTATATE PET/CT.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Tirosh A, Papadakis G, Millo C, Sadowski S, Herscovitch P,

Keywords: PET burden,

#1855 Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Predicts Progression-Free Survival (PFS) and Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)

Introduction: Patients with NETs have divergent survival, even when having the same site of primary tumor, tumor stage and grade. 68Ga-DOTATATE PET/CT has emerged as a sensitive imaging modality for detecting NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Tirosh A, Papadakis G, Millo C, Sadowski S, Herscovitch P,

Keywords: PET, 68Ga-DOTATATE, mortality,